IL243189A0 - Preparations containing 1-nk receptor antagonists for the treatment of pruritus - Google Patents
Preparations containing 1-nk receptor antagonists for the treatment of pruritusInfo
- Publication number
- IL243189A0 IL243189A0 IL243189A IL24318915A IL243189A0 IL 243189 A0 IL243189 A0 IL 243189A0 IL 243189 A IL243189 A IL 243189A IL 24318915 A IL24318915 A IL 24318915A IL 243189 A0 IL243189 A0 IL 243189A0
- Authority
- IL
- Israel
- Prior art keywords
- serlopitant
- pruritus
- receptor antagonist
- antagonist
- receptor
- Prior art date
Links
- FLNYCRJBCNNHRH-OIYLJQICSA-N 3-[(3ar,4r,5s,7as)-5-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-(4-fluorophenyl)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]cyclopent-2-en-1-one Chemical compound C1([C@H]2[C@@H]3CN(C[C@H]3CC[C@@H]2O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=2CCC(=O)C=2)=CC=C(F)C=C1 FLNYCRJBCNNHRH-OIYLJQICSA-N 0.000 title 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title 1
- 208000003251 Pruritus Diseases 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 229950011343 serlopitant Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361838784P | 2013-06-24 | 2013-06-24 | |
| US13/925,509 US8906951B1 (en) | 2013-06-24 | 2013-06-24 | Use of NK-1 receptor antagonists in pruritus |
| PCT/US2014/043811 WO2014209962A1 (en) | 2013-06-24 | 2014-06-24 | Use of nk-1 receptor antagonist serlopitant in pruritus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL243189A0 true IL243189A0 (en) | 2016-02-29 |
Family
ID=51230173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL243189A IL243189A0 (en) | 2013-06-24 | 2015-12-17 | Preparations containing 1-nk receptor antagonists for the treatment of pruritus |
Country Status (13)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| WO2016044784A1 (en) | 2014-09-19 | 2016-03-24 | Heron Therapeutics, Inc. | Emulson formulations of aprepitant |
| WO2016141341A1 (en) | 2015-03-04 | 2016-09-09 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| US9974742B2 (en) | 2016-02-01 | 2018-05-22 | Heron Therapeutics, Inc. | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
| CA3013288A1 (en) * | 2016-02-01 | 2017-08-10 | Heron Therapeutics, Inc. | Emulsion comprising an nk-1 receptor antagonist |
| JP2019519592A (ja) * | 2016-06-29 | 2019-07-11 | メンロ セラピューティクス インコーポレイテッド | 様々な掻痒状態を処置するためのニューロキニン−１アンタゴニストの使用 |
| KR20200054232A (ko) * | 2017-09-13 | 2020-05-19 | 반다 파마슈티칼즈, 인코퍼레이티드. | 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 |
| US11426408B2 (en) * | 2017-11-01 | 2022-08-30 | National University Of Singapore | Use of serotonergic drugs to treat virus-induced thrombocytopenia |
| JP7324210B2 (ja) * | 2018-01-31 | 2023-08-09 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッド | トファシチニブを含む局所製剤 |
| CN115015440B (zh) * | 2022-07-08 | 2024-10-15 | 江苏杜瑞制药有限公司 | 一种生物样品中纳呋拉啡的检测方法 |
| CN117503699A (zh) * | 2023-12-08 | 2024-02-06 | 斯坦德医药研发(江苏)有限公司 | 阿瑞匹坦口服液制剂及制剂制造方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030100565A1 (en) | 2001-09-21 | 2003-05-29 | Boehringer Ingelheim International Gmbh | Method for the treatment or prevention of atopic dermatitis |
| AR047439A1 (es) | 2004-01-27 | 2006-01-18 | Merck & Co Inc | Antagonistas del receptor hidroisoindolina taquiquinina |
| CN100582093C (zh) * | 2004-01-27 | 2010-01-20 | 默克公司 | 氢异二氢吲哚速激肽受体拮抗剂 |
| DE602006020450D1 (de) | 2005-07-11 | 2011-04-14 | Merck Sharp & Dohme | Ykinin-rezeptorantagonisten |
| US7893091B2 (en) | 2005-10-04 | 2011-02-22 | Merck Sharp & Dohme Corp. | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
| WO2007146224A2 (en) | 2006-06-12 | 2007-12-21 | Merck & Co., Inc. | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
| AU2007293393A1 (en) * | 2006-09-06 | 2008-03-13 | Merck & Co., Inc. | Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide |
| EP2089019A4 (en) | 2006-11-02 | 2011-05-04 | Merck Sharp & Dohme | POLYMORPHIC OF A HYDROISOINDOLINE TACHYKININE RECEPTOR ANTAGONIST |
| EP2141992A1 (en) | 2007-03-29 | 2010-01-13 | Merck & Co., Inc. | Combination therapy for the treatment-of lower urinary tract symptoms |
| RU2370265C1 (ru) * | 2008-03-04 | 2009-10-20 | Лев Давидович Раснецов | Гель, обладающий противовоспалительным и противоаллергическим действием |
-
2014
- 2014-06-24 RU RU2015154037A patent/RU2666219C2/ru active
- 2014-06-24 CN CN201480035219.3A patent/CN105473138A/zh active Pending
- 2014-06-24 MX MX2015017763A patent/MX366728B/es active IP Right Grant
- 2014-06-24 HK HK16111172.9A patent/HK1223820A1/zh unknown
- 2014-06-24 BR BR112015031724A patent/BR112015031724A2/pt not_active Application Discontinuation
- 2014-06-24 WO PCT/US2014/043811 patent/WO2014209962A1/en not_active Ceased
- 2014-06-24 JP JP2016521898A patent/JP2016523260A/ja not_active Ceased
- 2014-06-24 AU AU2014302694A patent/AU2014302694B2/en not_active Ceased
- 2014-06-24 CA CA2915474A patent/CA2915474A1/en not_active Abandoned
- 2014-06-24 EP EP14744671.0A patent/EP3013336A1/en not_active Withdrawn
- 2014-06-24 KR KR1020157035921A patent/KR20160023692A/ko not_active Ceased
-
2015
- 2015-12-14 PH PH12015502777A patent/PH12015502777A1/en unknown
- 2015-12-17 IL IL243189A patent/IL243189A0/en unknown
- 2015-12-18 MX MX2019008643A patent/MX2019008643A/es unknown
-
2019
- 2019-05-07 JP JP2019087897A patent/JP2019142960A/ja active Pending
-
2020
- 2020-01-14 AU AU2020200259A patent/AU2020200259A1/en not_active Abandoned
- 2020-02-04 PH PH12020500255A patent/PH12020500255A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019142960A (ja) | 2019-08-29 |
| PH12020500255A1 (en) | 2021-02-22 |
| MX366728B (es) | 2019-07-22 |
| MX2015017763A (es) | 2016-06-21 |
| MX2019008643A (es) | 2019-09-10 |
| WO2014209962A1 (en) | 2014-12-31 |
| AU2014302694A1 (en) | 2016-01-07 |
| CN105473138A (zh) | 2016-04-06 |
| JP2016523260A (ja) | 2016-08-08 |
| PH12015502777A1 (en) | 2016-03-21 |
| EP3013336A1 (en) | 2016-05-04 |
| BR112015031724A2 (pt) | 2017-07-25 |
| AU2014302694B2 (en) | 2019-10-17 |
| HK1223820A1 (zh) | 2017-08-11 |
| CA2915474A1 (en) | 2014-12-31 |
| RU2666219C2 (ru) | 2018-09-06 |
| AU2020200259A1 (en) | 2020-02-06 |
| RU2015154037A (ru) | 2017-07-28 |
| KR20160023692A (ko) | 2016-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2200048I1 (hu) | FcRn antagonisták és alkalmazásaik | |
| IL272279A (en) | Chimeric antigen receptor and methods of using it | |
| IL243189A0 (en) | Preparations containing 1-nk receptor antagonists for the treatment of pruritus | |
| SI2970473T1 (sl) | Kombinacija dr5 agonista in anti-pd-1 antagonista in postopek uporabe | |
| IL243459B (en) | Targeting of cytokine antagonists | |
| GB201305668D0 (en) | Avs6 Integrin Antagonists | |
| EP3020707A4 (en) | P2X4 RECEPTOR ANTAGONIST | |
| PL3046885T3 (pl) | Dodatek do mielenia cementu umożliwiający stosowanie osprzętu z PCW | |
| IL244356A0 (en) | Formulations for cgrp receptor antagonists | |
| ZA201506515B (en) | Novel sulfonamide trpa1 receptor antagonists | |
| ZA201604490B (en) | S1p3 antagonists | |
| HUP1300139A2 (en) | Phenoxypiperidine h3 antagonists | |
| PL2945963T3 (pl) | Inhibitory peptydowe nikotynowego receptora acetylocholiny | |
| ZA201801736B (en) | Progesterone receptor antagonist dosage form | |
| IL246091A0 (en) | Opioid antagonist formulations | |
| TH1501007504A (th) | การใช้เซอร์โลพิแทนต์ซึ่งเป็นnk-1 รีเซพเตอร์แอนทาโกนิสต์ ในอาการคัน | |
| GB201304666D0 (en) | Dopamine receptor antagonist | |
| GB201402028D0 (en) | Comparison tool in respect of WiFi usage in public places | |
| GB201323021D0 (en) | Use of kinase inhibitors | |
| GB201321227D0 (en) | Use of kinase inhibitors |